ArticleFrontiers in oncology2026
The role of AI-powered molecular profiling in the diagnosis and management of cancers of unknown primary: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular profiling (MP) and next-generation sequencing (NGS) have expanded the diagnostics evaluation of cancer by enabling genomic characterization that informs diagnosis and treatment selection. As the second leading cause of global mortality, cancer claimed nearly 10 million lives in 2020. Artificial intelligence (AI)-powered MP is increasingly recognized for its precision in diagnosing complex cancers, particularly cancers of unknown primary (CUP). Case presentation: We report a case of a 69-year-old male with a history of treated prostate cancer, initially diagnosed with CUP and suspected pancreaticobiliary malignancy. Conventional diagnostics, including imaging and immunohistochemistry, failed to identify the primary tumor, leading to ineffective therapies. AI-powered MP (Molecular Intelligence) revealed an 82% likelihood of renal cell carcinoma (RCC), prompting a targeted biopsy that confirmed RCC with sarcomatoid differentiation, enabling effective treatment with pembrolizumab and axitinib. Conclusions: This case highlights the potential role of AI-powered MP in resolving diagnostic uncertainty in CUP, where traditional methods like imaging and tumor markers are inconclusive. By identifying actionable biomarkers, MP facilitates personalized therapy, improving clinical outcomes. Further research is needed to validate the broader clinical utility of AI-driven MP as a decision-support tool for precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.